

Applicants : Jacob Bar-Tana and Ihor Bekersky  
Serial No. : 10/585,017  
Filed : June 28, 2008  
Page 12 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references, which are listed on the PTO-1449 Substitute form attached hereto as **Exhibit A**. Item 1 is a Supplementary European Search Report corresponding to a counterpart European Application. Items 2-6 were cited in item 1.

Items 2-3 are U.S. Patents, and in accordance with 37 C.F.R. §1.98(a)(2)(ii) copies of these items are not attached. Copies of items 1 and 4-6 are attached hereto as **Exhibits B-E**, respectively:

1. October 4, 2010 Supplementary European Search Report issued in connection with European Application No. EP 04 80 6716 (**Exhibit B**);
2. U.S. Patent No. 4,634,795, issued January 6, 1987 (Bar-Tana);
3. U.S. Patent No. 4,711,896, issued December 8, 1987 (Bar-Tana et al.);
4. PCT International Application Publication No. WO 99/00116 A2, published January 7, 1999 (Bar-Tana) (**Exhibit C**);
5. Russell et al., "Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by  $\beta,\beta'$ -tetramethylhexadecanedioic acid (MEDICA 16), Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15., no. 7, 1995 (**Exhibit D**); and

Applicants : Jacob Bar-Tana and Ihor Bekersky  
Serial No. : 10/585,017  
Filed : June 28, 2008  
Page 13 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

6. McCarty, M.F., "Peroxisome proliferators as adjuvants for the reverse-electron-transport therapy of obesity: An explanation for the large increase in metabolic rate of MEDICA 16-treated rats," *Medical Hypotheses*, vol. 53, no. 4, 1999 (**Exhibit E**).

According to 37 C.F.R. § 1.97(c), a Supplemental Information Disclosure Statement filed after the period specified in 37 C.F.R. § 1.97(b) shall be considered if accompanied by the fee set forth in 37 C.F.R. § 1.17(p) or a statement under 37 C.F.R. § 1.97(e). The required fee set forth in 37 C.F.R. § 1.97(p) is ONE HUNDRED EIGHTY DOLLARS (\$180.00) and authorization is given to charge this fee to Deposit Account No. 03-3125.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants : Jacob Bar-Tana and Ihor Bekersky

Serial No. : 10/585,017

Filed : June 28, 2008


Page 14 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

No fee, other than the total fee of \$735.00 (\$555.00 for a Three-Month Extension of Time and \$180.00 fee for filing a Supplemental Information Disclosure Statement), is deemed necessary in connection with the filing of this Amendment in Response to July 6, 2010 Office Action, Supplemental Information Disclosure Statement and Petition for a Three-Month Extension of Time. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
30 Rockefeller Plaza  
20<sup>th</sup> Floor  
New York, New York 10112  
(212) 278-0400

Certificate of Transmission	
I hereby certify that this correspondence is being transmitted via the Electronic Filing System (EFS) to the U.S. Patent and Trademark Office on <u>January 6, 2011</u> .	
 Adam C. Krol Reg. No. 64,351	<u>1/6/11</u> Date